A Study of PI3-Kinase Inhibitor GDC-0941

['lizbeth]

A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, in Patients With Locally Recurrent Or Metastatic Breast Cancer



This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of oral (PO) GDC-0941 administered with intravenous (IV) paclitaxel with and without and IV bevacizumab or IV trastuzumab in patients with locally recurrent or metastatic breast cancer.


http://www.clinicaltrials.gov/ct2/sh...cr=Open&rank=6